Insulin-Like Growth Factor I (IGF-I); cytoprotective effects, idea of replacement therapy in the healthy elderly subjects

Main Article Content

Hakki Dalcik Cannur Dalcik


Insulin-like growth factor-I (IGF-I) is one of the important molecule that has driven great interest in gerontology. The connection between IGF-I and the replacement therapy has been the center for many investigations for the past decade. IGF-I levels decline with age and has been considered to contribute to age-related decline in body activities. As adults age, there is a decline in the concentration of IGF-I. It has been postulated that the declines in both growth hormone (GH) and IGF-I, as it is evident in aged adults, may be associated with increased body fat, reduced muscle strength, decreased bone mass, and reduced lean body mass. This reduction may lead to overall body performance and thus may decrease the quality of life. In the present review, we have viewed the past history of the relevant publications to find a perception that would lead us to come close to the idea of the therapeutic step and provide a view of a possible IGF-I replacement therapy in the healthy elderly subjects. More specifically, this review will summarize and help to understand the effects and benefits of IGF-I system impacting on the aged organ systems. In addition, we aim to discuss the general functional properties of IGF-I and implications of its possible use as a replacement to the healthy elderly subjects and we will emphasis its downfalls and new perceptions. 

Article Details

How to Cite
DALCIK, Hakki; DALCIK, Cannur. Insulin-Like Growth Factor I (IGF-I); cytoprotective effects, idea of replacement therapy in the healthy elderly subjects. Medical Research Archives, [S.l.], v. 8, n. 6, june 2020. ISSN 2375-1924. Available at: <>. Date accessed: 15 july 2020. doi:
Research Articles


1. Salmon WD, Jr Daughaday W. A hormonally controllled serum factor which stimulates sulfate incorporation by cartilage in vitor. J Lab Clin Med. 1957;49:825-836
2. Rinderknecht E, Humbel RE. Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II. Proc Natl Acad Sci U S A. 1976; 73(7):2365-2369
3. Rotwein P. Molecular biology of IGF-I and IGF-II. In: Rosenfeld RG, Roberts Jr CT, eds. The IGF system: molecular biology, physiology and clinical applications, 17th ed. Totowa, NJ: Humana Press. 1999;19-36
4. LeRoith D. Insulin-like growth factors. N Engl J Med. 1997;336:633-640
5. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor-I. Proc Natl Acad Sci USA. 1999;96:7324-7329
6. Bright GM, Fierro-Renoy JF. A rationale fort he treatment of short stature in children with the combonation of recombonant human growth hormone (rhGH) and recombinant human insulin-like growth factor-I (rhIGF-I). Growth Horm IGF Res. 2020;52:101318-101325
7. Sun LY, Al-Regaiey K, Mastemak MM, Wang J, Bartke A. Local expression of GH and IGF-1 in the hippocampus of GH-deficient long-lived mice. Neurobiol Aging. 2005;26(6):929-37
8. Murphy LJ, Friesen HG. Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomized hypophysectomized rat. Endocrinol. 1988;122:325-332
9. Hofbauer LC, Rafferzeder M, Janssen OE, Gartner R. Insulin-like growth factor-I messenger ribonucleic acid expression in porcine thyroid follicles is regulated by thyrotropin and iodine. Eur J Endocrinol. 1995;132:605-610
10. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 1997;8:45-62
11. Ranke MB, Elmlinger M. Functional role of the insulin-like growth factor binding proteins. Horm Res. 1997;48:9-15
12. Collett-Solberg PF, Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine. 2000;12:121-136
13. Firth SM, McDougall F, McLachlan AJ, Baxter RC. Impaired blockade of insulin-like growth factor I (IGF-I)-induced hypoglycemia by IGF binding protein-3 analog with reduced ternary complex-forming ability. Endocrinology. 2002;143:1669-1676
14. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol. 2002;175:19-31
15. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278:E967–E976
16. Butler AA, Yakar S, Gewolb IH, Karas M, Okubo Y, LeRoith D. Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol Biochem Mol Biol. 1998;121:19-26
17. Lowe Jr WL, Adamo M, Werner H, Roberts Jr CT, LeRoith D. Regulation by fasting of insulin-like growth factor-I and its receptor: effects on gene expression and binding. J Clin Invest. 1989;84:619-626
18. Werner H, Roberts Jr CT, LeRoith D. The regulation of insulin-like growth factor-I receptor gene expression by positive and negative zinc-finger transcription factors. Adv Exp Med Biol. 1993;343:91-103
19. Hernandez-Sanchez C, Werner H, Roberts Jr CT, Woo EJ, Hum DW, Rosenthal SM, LeRoith D. Differential regulation of insulin-like growth factor-I (IGF-I) receptor gene expression by IGF-I and basic fibroblastic growth factor. J Biol Chem. 1997;272:4663-4670
20. Khandwala HM, Mc Cutcheon IE, Flyvbjerg A, Friend KE. The effects of Insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21(3):215-244
21. Puche JE, Castilla-Cortazar I. Human conditions of insülin-like growth factor-I (IGF-I) deficiency. J Trans Med, 2012;10:224-253
22. Parrizas M, Saltiel A, LeRoith D. Insulin-like growth factor I inhibits apoptosis using the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 1997;272:154-161
23. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R. Multiple signaling pathways of the insulin-like growth factor-1 receptor in protection of apoptosis. Mol Cell Biol. 1999;19:7203-7215
24. Deng X, Ruvolo P, Carr B, May WS. Survival function of ERK 1/2 as IL-3 activated, staurosporine-resistant Bcl-2 kinases. Proc Natl Acad Sci USA. 2000;97:1578-1583
25. Hu CL, Cowan RG, Harman RM, Quirk SM. Cell cycle progression and activation of Akt kinase are required for insulin-like growth factor-I mediated suppression of apoptosis in granulosa cells. Mol. Endocrinol. 2004;18(2):326-338
26. Kasprzak A, Kwasniewski W, Adamek A, Gozdzicka-Jozefiak A. Insulin-like growth factor (IGF) axis in cancerogenesis. Mutat Res Rev Mutat Res. 2016; 772:78-104
27. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34
28. Dimitriadis G, Parry-Billings M, Bevan S, Dunger D, Piva T, Krause U, Wegener G, Newsholme EA. Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro. Biochem J. 1992;285:269-274
29. Dalcik C, Yildirim GK, Dalcik H. The effects of ethanol on insulin-like growth factor-I immunoreactive neurons in the central nervous system. Saudi Med J. 2009;30:179-184
30. Selles MC, Fortuna JTS, Zappa-Villar MF, de Faria YPR, Souza AS, Suemoto CK, Leite REP, Rodriguez RD, Grinberg LT, Reggiani PC, Ferreira ST. Adenovirus-mediated transduction of insulin-like growth factor 1 protects hippocampal neurons from the toxicity of Aβ oligomers and prevents memory loss in an Alzheimer Mouse model. Mol Neurobiol. 2020;57(3):1473-1483
31. Ozkan S, Vural B, Filiz S, Costur P, Dalcik H. Placental expression of insulin-like growth factor-I, fibroblast growth factor-basic, and neural cell adhesion molecule in preeclampsia. J Matern Fetal Neonatal Med. 2008;21(11):831-8
32. Ozkan S, Vural B, Dalcik C, Tas A, Dalcik H. Placental expression of insulin-like growth factor-I, fibroblast growth factor-basic and neural cell adhesion molecule in pregnancies with small for gestational age fetuses. J Perinatol. 2008;28(7):468-74
33. Pennuto M, Pandey UB, Polanco MJ. Insulin-like growth factor 1 signaling in motor neuron and polyglutamine diseases: from molecular pathogenesis to therapeutic perspectives. Fron Neuroendocrinol. 2020; 57:100821-100831
34. Tamm I, Kikuchi T. Insulin-like growth factor-I (IGF-I), insulin and epidermal growth factor (EGF) are survival factors for density-inhibited, quiescent BALB/c-3T3 murine fibroblasts. J Cell Physiol. 1990;143:494-500
35. Yuan LJ, Wang XW, Wang HT, Zang M, Sun JW, Chen WF. G protein-coupled estrogen receptor is involved in the neuroprotective effect of IGF-1 against MPTP/MPP+-induced dopaminergic neuronal injury. J Steroid Biochem Mol Biol. 2019; 192:105384-105396
36. Bianchi VE, Locatelli V, Rizzi L. Neurotrophic and Neuroregenerative effects of GH/IGF1. Int J Mol Sci. 2017;18(11):2441-2466
37. Wang S, Hirschberg R. Role of growth factors in acute renal failure. Nephrol Dial Transplant. 1997;12:1560-1566
38. Ozkurkcugil C, Yardimoglu M, Dalcik H, Erdogan S, Gokalp A. Effects of insuli-like growth factor-I on apoptosis of rat testicular germ cells induced by testicular torsion. BJU International. 2004;93:1094-1097
39. Yeves Am, Burgos JI, Medina AJ, Villa-Abrille MC, Ennis IL. Cardioprotective role of IGF-I in the hypertrophied myocardium of the spontaneously hypertensive rats: A key effect on NHE-1 activity. Acta Physiol. 2018;224:13092-13100
40. Tung CL, Ju DT, Velmurugan BK, Ban B, Dung TD, Hsieh DJ, Viswanadha V, Day CH, Lin YM, Huang CY. Carthamus tinctorius L. Extracts activates insulin-like growth factor-I receptor signaling to inhibit FAS-death receptor pathway and suppress lipopolysaccharides-induced H9c2 cardiomyoblast cell apoptosis. Environ Toxicol. 2019;34(12):1320-1328
41. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest. 1997;100:1991-1999
42. Zang H, Yang Q, Li J. Eleutheroside B protects against acute kidney injury by activating IGF pathway. Molecules. 2019;24:3876-3893
43. Han Y, Wang S, Wang Y, Zeng S. IGF-I inhibits apoptosis of porcine primary granulosa cell by targeting degradation of BimEL. Int J Mol Sci. 2019;20:5356-5368
44. Canturk NZ, Canturk Z, Ozden M, Dalcik H, Yardimoglu M, Tulubas F. Protective effect of IGF-1 on experimental liver cirrhosis-induced common bile duct ligation. Hepatogastroenterol. 2003;50(54):2061-2066
45. García-Fernández M, Delgado G, Puche JE, González-Barón S, Castilla Cortázar I. Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats. Endocrinol. 2008;149:2433-2442
46. Russo VC, Kobayashi K, Najdovska S, Baker NL, Werther GA. Neuronal protection from glucose deprivation via modulation of glucose transport and inhibition of apoptosis: a role for the insulin-like growth factor system. Brain Res. 2004;29:40-53
47. Westwood AJ, et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. Neurology. 2014;82(18):1613-1619
48. Sonntag WE, Deak F, Ashpole N, Toth P, Csiszar A, Freeman W, Ungvari Z. Insulin-like growth factor-1 in CNS and cerebrovascular aging. Front Aging Neurosci. 2013;5:27
49. Quipildor GEF, Mao K, Hu Z, Novaj A, Cui MH, Gulinello M, Branch CA, Gubbi S, Patel K, Moellering DR, Tarantini S, Kiss T, Yabluchanskiy A, Ungvari Z, Sonntag WE, Huffman DM. Central IGF-I protects against features of cognitive and sensorimotor decline with aging in male mice. GeroScience. 2019;41:185-208
50. Pritera A, Blomeley C, Lopes E, Threlfell S, Merlini E, Burdakov D, Cragg S, Guillemot F, Ang SL. Dopamine neuron-derived IGF-I controls dopamine neuron firing, skill learning, and exploration. Proc Natl Acad Sci USA. 2019;26:116(9):3817-3826
51. Hansen M, Boesen A, Holm L, Flyvbjerg A, langberg H, Kjaer M. Local administration of insulin-like growth factor-I (IGF-I) stimulates tendon collagen synthesis in humans. Scandinavian Journal of Medicine & Science in Sports. 2012;113(9):1432-1438
52. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14:20-39
53. Harley CB, Vaziri H, Counter CM, Allsopp RC. The telomere hypothesis of cellular aging. Exp Gerontol. 1992;27:375-382
54. Masoro EJ. Overview of caloric restriction and ageing. Mech Ageing Dev. 2005;126:913-922
55. D’Costa AP, Ingram RL, Lenham JE, Sonntag WE. The regulation and mechanisms of action of growth hormone and insulin-like growth factor 1 during normal ageing. J Reprod Fertil Suppl. 1993;46:87-98
56. Ghigo E, Arvat E, Gianotti L, et al. Human ageing and the GH-IGF-I axis. J Ped Endocrinol Metab. 1996;9:271-278
57. Arvat E, Giordano R, Gianotti L, Broglio F, Camanni F, Ghigo E. Neuroendocrinology of the human growth hormone-insulin-like growth factor I axis during ageing. Growth Horm IGF Res. 1999;9:111-115
58. Arvat E, Broglo F, and Ghigo E. Insulin-like growth factor 1: implication in aging. Drugs Aging. 2000;16:29-40
59. Bartke A, Chandrashekar V, Dominici F, Turyn D, Kinney B, Steger R, Kopchick JJ. Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights. Biogerontology. 2003;4:1-8
60. Bartke A, Darcy J. GH and Ageing: pitfalls and new insights. Best Pract Res Clin Endocrinol Metab. 2017;31:113-125
61. Russo A, Paret C, Alt F, Burhenne J, Fresnais M, Wagner W, Glaser M, Bender H, Huprich S, et al. Ceritinib-induced regression of an insulin-like growth factor-driven neuroepithelial brain tumor. Int J Mol Sci. 2019;20(17):4267-4286
62. Glick RP, Unterman TG, Van Der Voude M, Blaydes LZ. Insulin and insulin-like growth factors in central nervous system tumors. J Neurosurg. 1992;77:445-450
63. Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut. 1999;44:704-708
64. Scharf JG, Schmidt-Sandte W, Pahernick SA, Ramadori G, Braulke T, Hartmann H. Characterization of insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis. 1998;19:2121-2128
65. Kotsantis I, Economopoulou P, Psyrri A, Maratou E, Pectasides D, Gogas H, Kentepozidis N, Mountzios G, Dimitrias G, Giannouli S. Prognostic significance of IGF-1 signalling pathway in patients with advanced non-small cell lung cancer. Anticancer Res. 2019;39(8):4185-4190
66. Hoffmann M, Gogola J, Ptak A. Adiponectin reverses the proliferative effects of estradiol and IGF-I in human epithelial ovarian cancer cells by downregulating the expression of their receptors. Horm Cancer. 2018;9(3):166-174
67. Bjorntorp E, Wickelgren R, Bjarnason R, Swanbeck G, Carlsson LM, Lindahl A. No evidence for involvement of the growth hormone/insulin-like growth factor-1 axis in psoriasis. J Invest Dermatol. 1997;109:661-665
68. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323:1-6
69. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med. 2007;146:104-115
70. Backeljauw PF, Underwood LE. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome. J Clin Endocrinol Metab. 1996;81:3312-3317
71. Laron Z, Klinger B, Jensen LT, Erster B. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol (Oxf). 1991;35(2):145-50
72. Klinger B, Jensen LT, Silbergeld A, Laron Z. Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome. Clin Endocrinol (Oxf). 1996;45(4):423-9
73. Savage MO, Dunger DB. Recombinant IGF-I therapy in insulin-dependent diabetes mellitus. Diabetes Metab. 1996;22:257-260
74. Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab. 1996;81:3864-3870
75. Vogt PM, Lehnhardt M, Wagner D, Jansen V, Krieg M, Steinau HU. Determination of endogenous growth factors in human wound fluid: temporal presence and profiles of secretion. Plast Reconstr Surg. 1998;102:117-123
76. Ye P, CarsonJ, D’Ercole AJ. In vivo actions of insulin-likegrowth factor-I (IGF-I) on brain myelination: studies of IGF-I and IGF binding protein-1 (IGFBP-1) transgenic mice. J Neurosci. 1995;15:7344-7356
77. Caicedo D, Diaz O, Devesa P, Devesa J. Growth hormone (GH) and cardiovascular system. Int J Mol Sci. 2018;19(1):290-310
78. Martovytskyi DV, Shelest OM, Kravchun PG. Effect of endostatin and insülin-like growth factor-1 on angiogenesis in patients with acute mycardial infaction with obesity under the influence of zofenopril. Wiad Lek. 2020;73(1):63-67
79. Jung S, Kim JH, Yim C, Lee M, Kang HJ, Choi D. Therapeutic effects of a mesenchymal stem cell-based insülin-like growth factor-I/enhanced green fluorescent protein dual gene sorting system in a mycardial infarction rat model. Mol Med Rep. 2018;18(6):5563-5571
80. Scheinowitz M, Abramov D, Elder M. The role of insulin-like and basic fibroblast growth factors on ischemic and infarcted myocardium: a mini review. Int J Cardiol. 1997;59:1-5
81. Dore S, Kar S, Quition R. Insulin-like growth factor I protects and rescues hippocampal neurons against beta-amyloid-and human amylin-induced toxicity. Proc Natl Acad Sci USA. 1997;94:4772-4777
82. Walser M, Oscarsson J, Aberg MAI, Svesson J, Isgaard J, Aberg ND. Effects of peripheral administration of GH and IGF-I on gene expression in the hippocampus of hypophysectomised rats. Neuro Endocrinol Lett. 2019;39(7):525-531
83. Hong M, Lee VM. Insulin-like growth factor-I regulate tau phosphorylation in cultured human neurons. J Biol Chem. 1997;272:19547-19553
84. Burman P, Deijen JB. Quality of life and cognitive function in patients with pituitary insufficiency. Psychother Psychosomat. 1998;67:154-167
85. Aleman A, Verhaar HJJ, De Haan EH, De Vries WR, Samson MM, Drent ML, Van der Veen EA, Koppeschaar HP. Insulin-like growth factor-I and cognitive function in healthy older men. J Clin Endocrinol Metab. 1999;84:471-475
86. Sadaba MC, Martin-Estal I, Puche JE, Castilla-Cortazar I. Insulin-like growth factor-1 (IGF-1) therapy: mitochondrial disfunction and disease. Biochimica et Biophysica Acta. 2016;1862:1267-1278
87. Chapman IM, Bach MA, Cauter EV, Farmer M, Krupa D, Taylor AM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. The Journal of Clinical Endocrinology and Metabolism. 1996;81(12):4249-4257
88. Blackman MR, Sorkin JD, Munzer T, et. al. Growth hormone and sex steroid administration in healthy aged women and men. JAMA. 2002;288(18):2282-2292
89. Bahamonde M, Misra M. Potential applications for rhIGF-I: Bone disease and IGF-I. Growth Horm IGF Res. 2020;52:101317-101321
90. Cuttica CM, Castoldi L, Gorrini GP, Peluffo F, Delitala G, Filippa P, Fanciulli G, Giusti M. Effects of six-month administration of recombinant human growth hormone to healthy elderly subjects. Aging Clinical and Experimental Research. 2014;9:193-197
91. Lovett-Racke AE, Bittner P, Cross AH, Carlino JA, Racke MK. Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J Clin Invest. 1998;101:1797-1804
92. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab. 2000;85:1518-1524
93. Carmody D, Ladsaria SS, Buikema RK, Semple RK, Greeley AW. Successful rhIGF-I treatment for over 5 years in a patient with severe insuli resistance due to homozygous insulin resistance due to homozygous insulin receptor mutation. Diabet Med. 2016;33(3):8-12

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.